麦济生物港股IPO:2024年亏损1.78亿,张江集团、康哲药业等参股

面包财经
Aug 06

近期,麦济生物向港交所主板递交上市申请,中金公司担任独家保荐人。麦济生物创立于2016年,致力于围绕过敏性及自身免疫疾病等领域未被满足的临床需求,开展创新抗体药物的自主研发及商业化工作。麦济生物构建了TEADA抗体发现平台,能高效筛选生物学活性高、成药性好的候选分子。目前,旗下靶向IL-4Rα长效抗体药物MG-K10在中重度特应性皮炎(AD)、中重度哮喘的Ⅱ期临床中,显著改善患者症状,且给药间隔...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10